AAAAAA

   
Results: 1-24 |
Results: 24
GEMCITABINE PLUS CISPLATIN COMBINATION GIVEN WITH AMIFOSTINE (GAP) TOHEAVILY PRETREATED PATIENTS WITH GYNECOLOGIC AND PERITONEAL CANCERS -TOLERANCE AND ACTIVITY IN OVARIAN-CANCER
Authors: SAFRA T JEFFERS S SORICH J MUGGIA FM
Citation: T. Safra et al., GEMCITABINE PLUS CISPLATIN COMBINATION GIVEN WITH AMIFOSTINE (GAP) TOHEAVILY PRETREATED PATIENTS WITH GYNECOLOGIC AND PERITONEAL CANCERS -TOLERANCE AND ACTIVITY IN OVARIAN-CANCER, Anti-cancer drugs, 9(6), 1998, pp. 511-514
PHASE-I AND PHARMACOLOGICAL STUDY OF ESTRAMUSTINE PHOSPHATE AND SHORTINFUSIONS OF PACLITAXEL IN WOMEN WITH SOLID TUMORS
Authors: GARCIA AA KERENROSENBERG S PARIMOO D ROGERS M JEFFERS S KODA R MUGGIA FM
Citation: Aa. Garcia et al., PHASE-I AND PHARMACOLOGICAL STUDY OF ESTRAMUSTINE PHOSPHATE AND SHORTINFUSIONS OF PACLITAXEL IN WOMEN WITH SOLID TUMORS, Journal of clinical oncology, 16(9), 1998, pp. 2959-2963
PHASE-II STUDY OF LIPOSOMAL DOXORUBICIN IN REFRACTORY OVARIAN-CANCER - ANTITUMOR-ACTIVITY AND TOXICITY MODIFICATION BY LIPOSOMAL ENCAPSULATION
Authors: MUGGIA FM HAINSWORTH JD JEFFERS S MILLER P GROSHEN S TAN M ROMAN L UZIELY B MUDERSPACH L GARCIA A BURNETT A GRECO FA MORROW CP PARADISO LJ LIANG LJ
Citation: Fm. Muggia et al., PHASE-II STUDY OF LIPOSOMAL DOXORUBICIN IN REFRACTORY OVARIAN-CANCER - ANTITUMOR-ACTIVITY AND TOXICITY MODIFICATION BY LIPOSOMAL ENCAPSULATION, Journal of clinical oncology, 15(3), 1997, pp. 987-993
USE OF F-18 FDG AND PET IN ASSESSMENT OF MINIMAL DISEASE AFTER TREATMENT OF EPITHELIAL OVARIAN-CANCER
Authors: CONTI PS HORWICH T ROMAN L MUDERSPACH L JEFFERS S MORROW CP MUGGIA FM
Citation: Ps. Conti et al., USE OF F-18 FDG AND PET IN ASSESSMENT OF MINIMAL DISEASE AFTER TREATMENT OF EPITHELIAL OVARIAN-CANCER, The Journal of nuclear medicine, 38(5), 1997, pp. 545-545
TOLERANCE OF PACLITAXEL 3-HOUR INFUSION WITH AND WITHOUT GRANULOCYTE-COLONY-STIMULATING FACTOR ON A BIWEEKLY SCHEDULE
Authors: GARCIA AA PARIMOO D DIMERY I ROGERS M JEFFERS S MUGGIA FM
Citation: Aa. Garcia et al., TOLERANCE OF PACLITAXEL 3-HOUR INFUSION WITH AND WITHOUT GRANULOCYTE-COLONY-STIMULATING FACTOR ON A BIWEEKLY SCHEDULE, Seminars in oncology, 24(6), 1997, pp. 62-66
PHASE I II STUDY OF INTRAPERITONEAL FLOXURIDINE AND PLATINUMS (CISPLATIN AND/OR CARBOPLATIN)/
Authors: MUGGIA FM JEFFERS S MUDERSPACH L ROMAN L ROSALES R GROSHEN S SAFRA T MORROW CP
Citation: Fm. Muggia et al., PHASE I II STUDY OF INTRAPERITONEAL FLOXURIDINE AND PLATINUMS (CISPLATIN AND/OR CARBOPLATIN)/, Gynecologic oncology, 66(2), 1997, pp. 290-294
FAILURE OF PRETREATMENT WITH INTRAVENOUS FOLIC-ACID TO ALTER THE CUMULATIVE HEMATOLOGIC TOXICITY OF LOMETREXOL
Authors: MUGGIA FM SYNOLD TW NEWMAN EM JEFFERS S LEICHMAN LP DOROSHOW JH JOHNSON K GROSHEN S
Citation: Fm. Muggia et al., FAILURE OF PRETREATMENT WITH INTRAVENOUS FOLIC-ACID TO ALTER THE CUMULATIVE HEMATOLOGIC TOXICITY OF LOMETREXOL, Journal of the National Cancer Institute, 88(20), 1996, pp. 1495-1496
SEVERE NEUROTOXICITY FROM VINORELBINE-PACLITAXEL COMBINATIONS
Authors: PARIMOO D JEFFERS S MUGGIA FM
Citation: D. Parimoo et al., SEVERE NEUROTOXICITY FROM VINORELBINE-PACLITAXEL COMBINATIONS, Journal of the National Cancer Institute, 88(15), 1996, pp. 1079-1080
PHASE-I AND PHARMACOKINETIC STUDY OF ORAL UFT, A COMBINATION OF THE 5-FLUOROURACIL PRODRUG TEGAFUR AND URACIL
Authors: MUGGIA FM WU XY SPICER D GROSHEN S JEFFERS S LEICHMAN CG LEICHMAN L CHAN KK
Citation: Fm. Muggia et al., PHASE-I AND PHARMACOKINETIC STUDY OF ORAL UFT, A COMBINATION OF THE 5-FLUOROURACIL PRODRUG TEGAFUR AND URACIL, Clinical cancer research, 2(9), 1996, pp. 1461-1467
REPLY TO COMMENT BY COMAY,E. ON THE LONGITUDINAL MAGNETIC-FIELD OF CIRCULARLY-POLARIZED ELECTROMAGNETIC-WAVES
Authors: EVANS MW JEFFERS S
Citation: Mw. Evans et S. Jeffers, REPLY TO COMMENT BY COMAY,E. ON THE LONGITUDINAL MAGNETIC-FIELD OF CIRCULARLY-POLARIZED ELECTROMAGNETIC-WAVES, Foundations of physics letters, 9(6), 1996, pp. 587-593
ABDOMINOPELVIC HYPERTHERMIA AND INTRAPERITONEAL CARBOPLATIN IN EPITHELIAL OVARIAN-CANCER - FEASIBILITY, TOLERANCE AND PHARMACOLOGY
Authors: FORMENTI SC SHRIVASTAVA PN SAPOZINK M JOZSEF G CHAN KK JEFFERS S MORROW PC MUGGIA FM
Citation: Sc. Formenti et al., ABDOMINOPELVIC HYPERTHERMIA AND INTRAPERITONEAL CARBOPLATIN IN EPITHELIAL OVARIAN-CANCER - FEASIBILITY, TOLERANCE AND PHARMACOLOGY, International journal of radiation oncology, biology, physics, 35(5), 1996, pp. 993-1001
THE INVERSE FARADAY-EFFECT, FERMION SPIN, AND B(3)
Authors: EVANS MW ROY S JEFFERS S
Citation: Mw. Evans et al., THE INVERSE FARADAY-EFFECT, FERMION SPIN, AND B(3), Nuovo cimento della Societa italiana di fisica. B, Relativity, classical and statistical physics, 110(12), 1995, pp. 1473-1479
LIPOSOMAL DOXORUBICIN - ANTITUMOR-ACTIVITY AND UNIQUE TOXICITIES DURING 2 COMPLEMENTARY PHASE-I STUDIES
Authors: UZIELY B JEFFERS S ISACSON R KUTSCH K WEITSAO D YEHOSHUA Z LIBSON E MUGGIA FM GABIZON A
Citation: B. Uziely et al., LIPOSOMAL DOXORUBICIN - ANTITUMOR-ACTIVITY AND UNIQUE TOXICITIES DURING 2 COMPLEMENTARY PHASE-I STUDIES, Journal of clinical oncology, 13(7), 1995, pp. 1777-1785
INTRAPERITONEAL 5-FLUORO-2'-DEOXYURIDINE (FUDR) AND (S)-LEUCOVORIN FOR DISEASE PREDOMINANTLY CONFINED TO THE PERITONEAL-CAVITY - A PHARMACOKINETIC AND TOXICITY STUDY
Authors: ISRAEL VK JIANG C MUGGIA FM TULPULE A JEFFERS S LEICHMAN L MORROW CP ROMAN L LEICHMAN CG CHAN KK
Citation: Vk. Israel et al., INTRAPERITONEAL 5-FLUORO-2'-DEOXYURIDINE (FUDR) AND (S)-LEUCOVORIN FOR DISEASE PREDOMINANTLY CONFINED TO THE PERITONEAL-CAVITY - A PHARMACOKINETIC AND TOXICITY STUDY, Cancer chemotherapy and pharmacology, 37(1-2), 1995, pp. 32-38
LIKE COUNTING DECKCHAIRS ON THE TITANIC - A STUDY OF INSTITUTIONAL RACISM AND HOUSING ALLOCATIONS IN HARINGEY AND LAMBETH
Authors: JEFFERS S HOGGETT P
Citation: S. Jeffers et P. Hoggett, LIKE COUNTING DECKCHAIRS ON THE TITANIC - A STUDY OF INSTITUTIONAL RACISM AND HOUSING ALLOCATIONS IN HARINGEY AND LAMBETH, Housing studies, 10(3), 1995, pp. 325-344
PACLITAXEL 3-HOUR INFUSION GIVEN ALONE AND COMBINED WITH CARBOPLATIN - PRELIMINARY-RESULTS OF DOSE-ESCALATION TRIALS
Authors: MUGGIA FM VAFAI D NATALE R ISRAEL V ZARETSKY S MCRAE A ROGERS M JEFFERS S
Citation: Fm. Muggia et al., PACLITAXEL 3-HOUR INFUSION GIVEN ALONE AND COMBINED WITH CARBOPLATIN - PRELIMINARY-RESULTS OF DOSE-ESCALATION TRIALS, Seminars in oncology, 22(4), 1995, pp. 63-66
A FIXED-RATIO COMBINATION OF URACIL AND FTORAFUR (UFT) WITH LOW-DOSE LEUCOVORIN - AN ACTIVE ORAL REGIMEN FOR ADVANCED COLORECTAL-CANCER
Authors: SALTZ LB LEICHMAN CG YOUNG CW MUGGIA FM CONTI JA SPIESS T JEFFERS S LEICHMAN LP
Citation: Lb. Saltz et al., A FIXED-RATIO COMBINATION OF URACIL AND FTORAFUR (UFT) WITH LOW-DOSE LEUCOVORIN - AN ACTIVE ORAL REGIMEN FOR ADVANCED COLORECTAL-CANCER, Cancer, 75(3), 1995, pp. 782-785
PACLITAXEL (TAXOL) IN HEAVILY PRETREATED OVARIAN-CANCER - ANTITUMOR-ACTIVITY AND COMPLICATIONS
Authors: UZIELY B GROSHEN S JEFFERS S MORRIS M RUSSELL C ROMAN L MUDERSPACH L MUGGIA F
Citation: B. Uziely et al., PACLITAXEL (TAXOL) IN HEAVILY PRETREATED OVARIAN-CANCER - ANTITUMOR-ACTIVITY AND COMPLICATIONS, Annals of oncology, 5(9), 1994, pp. 827-833
LOW-DOSES OF DEXAMETHASONE PROTECT AGAINST PACLITAXEL (TAXOL)-RELATEDHYPERSENSITIVITY REACTIONS FOLLOWING CYCLE-1
Authors: UZIELY B JEFFERS S MUGGIA F
Citation: B. Uziely et al., LOW-DOSES OF DEXAMETHASONE PROTECT AGAINST PACLITAXEL (TAXOL)-RELATEDHYPERSENSITIVITY REACTIONS FOLLOWING CYCLE-1, Annals of oncology, 5(5), 1994, pp. 474-474
AN EXPERIMENT TO DETECT EMPTY WAVES
Authors: JEFFERS S SLOAN J
Citation: S. Jeffers et J. Sloan, AN EXPERIMENT TO DETECT EMPTY WAVES, Foundations of physics letters, 7(4), 1994, pp. 333-341
REFLEXIVITY AND UNCERTAINTY IN THE RESEARCH PROCESS
Authors: HOGGETT P JEFFERS S HARRISON L
Citation: P. Hoggett et al., REFLEXIVITY AND UNCERTAINTY IN THE RESEARCH PROCESS, Policy and politics, 22(1), 1994, pp. 59-70
INTRAPERITONEAL 5-FLUORO-2'-DEOXYURIDINE WITH ESCALATING DOSES OF LEUCOVORIN - PHARMACOLOGY AND CLINICAL TOLERANCE
Authors: MUGGIA FM TULPULE A RETZIOS A CHEN F JEFFERS S LEICHMAN CG LEICHMAN L SPEARS CP CHAN KK
Citation: Fm. Muggia et al., INTRAPERITONEAL 5-FLUORO-2'-DEOXYURIDINE WITH ESCALATING DOSES OF LEUCOVORIN - PHARMACOLOGY AND CLINICAL TOLERANCE, Investigational new drugs, 12(3), 1994, pp. 197-206
PHASE-I AND PHARMACOLOGICAL STUDY OF LIPOSOMAL DAUNORUBICIN (DAUNOXOME)
Authors: GUAGLIANONE P CHAN K DELAFLORWEISS E HANISCH R JEFFERS S SHARMA D MUGGIA F
Citation: P. Guaglianone et al., PHASE-I AND PHARMACOLOGICAL STUDY OF LIPOSOMAL DAUNORUBICIN (DAUNOXOME), Investigational new drugs, 12(2), 1994, pp. 103-110
INTRAPERITONEAL CARBOPLATIN AND ETOPOSIDE FOR PERSISTENT EPITHELIAL OVARIAN-CANCER - ANALYSIS OF RESULTS BY PRIOR SENSITIVITY TO PLATINUM-BASED REGIMENS
Authors: MUGGIA FM GROSHEN S RUSSELL C JEFFERS S CHEN SC SCHLAERTH J CURTIN J MORROW CP
Citation: Fm. Muggia et al., INTRAPERITONEAL CARBOPLATIN AND ETOPOSIDE FOR PERSISTENT EPITHELIAL OVARIAN-CANCER - ANALYSIS OF RESULTS BY PRIOR SENSITIVITY TO PLATINUM-BASED REGIMENS, Gynecologic oncology, 50(2), 1993, pp. 232-238
Risultati: 1-24 |